[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Associazione Italiana Ematologia Oncologia Pediatrica\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100621281","real-world-pediatric-oncology-rehabilitation-in-italy--rewori--100621281",false,"NCT07368582","Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )","Real World Pediatric Oncology Rehabilitation in Italy (ReWori) Study Protocol: Prognostic Factors of Functional Abilities in Children, Adolescents and Young Adults With Cancer Undergoing Rehabilitation","REWORI","Inclusion Criteria:\n\n* Diagnosis of cancer,\n* Children, adolescents and young adults aged between 0 and 24 years old,\n* Children, adolescents and young adults at any stage of treatment and off therapy,\n* Children, adolescents and young adults referred to the Rehabilitation Service of AIEOP centres and Rehabilitation Centres that provide rehabilitation care for paediatric and young adult cancer patients involved in the study.\n\nExclusion Criteria:\n\n* Failure to sign the consent\u002Fassent form for participation in the study by the subject and\u002For by the person exercising parental authority.","ALL","0 Months","24 Years",{"count":21,"type":22},249,"ESTIMATED","OBSERVATIONAL","This observational study aims to describe changes in the functional abilities of children, adolescents and young adults with cancer who are undergoing physiotherapy or neuropsychomotor rehabilitation. This is real-world study aiming to describe normal rehabilitation pathways in many different hospitals or rehabilitation centres in Italy.\n\nThe primary research question is:\n\n1\\) What are the longitudinal changes in functional abilities among these patients receiving physiotherapy or neuropsychomotor rehabilitation?\n\nThe secondary research questions are:\n\n1. What types of rehabilitation practices are implemented across AIEOP centres?\n2. What are the rehabilitation needs among patients undergoing physiotherapy or neuropsychomotor rehabilitation?\n3. How does health-related quality of life differ across the various stages of the rehabilitation pathway? Participants undergoing usual rehabilitation treatment are evaluated on their functional abilities on a monthly basis. If they agree to participate in this study, the main characteristics of the rehabilitation treatment and the monthly evaluation are collected.",[26,27,28,29,30,31],"Pediatric Cancer","Pediatric Cancer Patients","Pediatric Oncology","Rehabilitation","Motor Outcomes","Physical Therapy",[33,34,35,36,37,38,39,40],"pediatric oncology","rehabilitation","motor performance","physical therapy","children","adolescents","young adults","exercise","RECRUITING","2026-03-24",{"date":44,"type":45},"2026-03-25","ACTUAL",{"date":47,"type":45},"2024-07-19",{"date":49,"type":22},"2029-09-30",{"name":51,"class":52},"Associazione Italiana Ematologia Oncologia Pediatrica","OTHER",13,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100423443","phase-2-treatment-study-for-children-and-adolescents-with-acute-promyelocytic-leukemia-100423443","NCT04793919","Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia","Inclusion Criteria:\n\n* Newly diagnosed APL confirmed by the presence of PML\u002FRARα fusion gene\n* Age \\\u003C18 years\n* Written informed consent by parents or legal guardians\n\nExclusion Criteria:\n\n* Patients with a clinical diagnosis of APL but subsequently found to lack PML\u002FRARα rearrangement should be withdrawn from the study and treated on an alternative protocol\n* Significant liver dysfunction (bilirubin serum levels \\>3 mg\u002FdL, ALT\u002FAST serum levels greater than 5 times the normal values)\n* Creatinine serum levels \\>2 times the normal value for age\n* Significant arrhythmias, EKG abnormalities (\\*see below), other cardiac contraindications (L-FEV \\\u003C50% or LV-FS \\\u003C28%)\n* Neuropathy\n* Concurrent active malignancy\n* Uncontrolled life-threatening infections\n* Pregnant or lactating female\n* Patients who had received alternative therapy (APL not initially suspected; ATRA and\u002For ATO not available","18 Years",{"count":62,"type":22},89,"INTERVENTIONAL",[65],"PHASE2","The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.",[68],"Acute Promyelocytic Leukemia","2024-04-12",{"date":71,"type":45},"2024-04-15",{"date":73,"type":45},"2019-10-09",{"date":75,"type":22},"2027-10-10",{"name":51,"class":52},31,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":60,"enrollmentInfo":85,"targetDuration":87,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100252049","prospective-study-registry-of-peripheral-neuroblastic-tumours-presenting-with-spinal-canal-involvement-sci-100252049","NCT02559804","Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)","NB-SCI","Inclusion Criteria:\n\n* Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse\u002Fprogression)\n* No previous chemotherapy, except steroids, in the last 6 months\n* Age \\\u003C18 years\n* Minimal planned follow-up of 5 years\n* Parent\u002Fpatient written informed consent (Appendix 1(A,B,C))\n\nExclusion Criteria:\n\n* Invasion of intervertebral foramina only",{"count":86,"type":22},150,"5 Years","To describe the natural history of peripheral neuroblastic tumour presenting with SCI and evaluate the combined effects of different risk factors on the eventual neurologic and orthopaedic outcomes",[90],"Neuroblastic Tumors",{"date":71,"type":45},{"date":93,"type":4},"2014-05",{"date":95,"type":22},"2029-05",{"name":51,"class":52},1,""]